A compound composition for preventing and treating shrimp hepatocellular carcinoma and its preparation method
The combination of albendazole, ivermectin, and glycyrrhizic acid monoammonium salt has solved the treatment problem of shrimp hepatocystis disease, achieving safe and efficient prevention and control, reducing the pathogen load of shrimp hepatocystis, and ensuring aquaculture benefits.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-30
- Publication Date
- 2026-07-03
AI Technical Summary
Current technology has not yet found a cheap, safe, and effective drug to treat shrimp hepatic cysticercosis. Furthermore, shrimp hepatic cysticercosis is highly insidious and difficult to detect in its early stages, which affects the profitability of aquaculture.
A compound composition of albendazole, ivermectin, and glycyrrhizic acid monoammonium salt is used to inhibit the synthesis of microtubule protein in insects, act on the neuromuscular junction to cause paralysis and death of insects, and combine antioxidant, anti-inflammatory and immunomodulatory effects. It is prepared into different dosage forms such as tablets, capsules and granules to suit different drug administration scenarios in aquaculture.
It significantly reduces the pathogenic load of EHP in shrimp, reduces the dosage of single-drug treatment and the risk of drug resistance, and ensures the healthy and sustainable development of aquaculture.